Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancers × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 45 Lung Neoplasms 10 Neoplasms 6 Neoplasm Metastasis 6 Lymphoma, Large-Cell, Anaplastic 6 Multiple Myeloma 4 Lymphoma 4 Granuloma, Plasma Cell 4 Adenocarcinoma 4 Neuroblastoma 3 Colorectal Neoplasms 3 Uveal Melanoma 2 Recurrence 2 Hematologic Neoplasms 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Carcinoma, Renal Cell 2 Carcinoma 2 ALK-positive NSCLC 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma, Alveolar 1 Relapsed Pediatric Solid Tumor 1 Rare Tumor 1 Multiple Endocrine Neoplasia Type 2a 1 Melanoma 1 Lymphoma, Non-Hodgkin 1

Interventions

Surveys and Questionnaires 5 pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 satraplatin 1 ridaforolimus 1 ixazomib 1 X-Rays 1 Videotape Recording 1 Valproic Acid 1 Trastuzumab 1 Sugars 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Injections, Subcutaneous 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡